Over a week ago
On The Fly
The most talked about and…
Show Hide Related Items >> <<
05/11/23 FDIC proposes rule for special assessment on big banks for cost recovery 05/08/23 Zions Bancorp director bought $480K in common stock 05/04/23 Zions Bancorp trading resumes 05/04/23 Zions Bancorp trading halted, volatility trading pause 05/03/23 North American rail traffic down 4.6% for the week ending April 29 04/26/23 North American rail traffic down 3% for the week ending April 22 04/21/23 Treasury proposes tighter oversight of non-banks that pose systemic risk 02/13/23 Rocket Companies announces retirement of CEO Jay Farner and succession plan 12/14/22 CEO of Rocket Companies Farner buys over $600K in company stock 02/13/23 Brainsway announces appointment of Beohm as new chairman 01/12/23 Ormat Technologies secures financing agreement for Iien Geothermal Project $221.76 / +3.925 (+1.80%)
05/18/23 Norfolk Southern and union reach agreement on paid sick leave per year 05/18/23 Norfolk Southern sees 'three tough months' in Q2 05/17/23 North American rail traffic down 5.4% for the week ending May 13 05/10/23 North American rail traffic down 6.7% for the week ending May 6 $112.01 / -2.785 (-2.43%)
05/12/23 Soros Fund buys American Water, exits D.R. Horton in Q1 04/28/23 Nike signs Kevin Durant to lifetime contract 04/25/23 Nike expands relationship with Cognizant 04/17/23 Nordstrom appoints Eric Sprunk to Board of Directors 03/01/23 Moog names Mark Trabert as new COO 02/03/23 Moog increases quarterly dividend 4% to 27c per share 05/19/23 Intercept 'disappointed' in outcome of FDA's advisory meeting 05/19/23 Intercept announces outcome of FDA meeting to review NDA for obeticholic acid 05/19/23 FDA panel votes 12-2 against Intercept's pre-cirrhotic fibrosis treatment 05/19/23 Intercept announces Nasdaq halt of trading, FDA advisory committee meeting 05/19/23 Foot Locker falls -27.6% 05/19/23 Foot Locker falls -25.6% 05/19/23 Foot Locker falls -25.2% 05/19/23 Foot Locker down 23% after Q1 earnings miss, FY23 guidance cut 04/26/23 Cathie Wood's ARK Investment sold 210K shares of DraftKings today 04/25/23 Nevada reports March statewide gaming win down 3.18% to $1.31B 04/11/23 Cathie Wood's ARK Investment sold 63.4K shares of DraftKings today 04/10/23 Cathie Wood's ARK Investment sold 347K shares of DraftKings today 05/09/23 Dice Therapeutics director sells $3.24M in common stock 03/30/23 Dice Therapeutics discloses $14.8M purchase of common stock by Ra Capital 01/11/23 Cirrus the 'winner' for change to solid state buttons on iPhone 15, says Kuo 02/02/23 Conmed: Results impacted by implementation of warehouse management system 03/06/23 BlackLine announces leadership succession 12/08/22 BlackLine to reduce global workforce by about 5% 05/22/23 United Airlines to support Live Activities for iPhone 05/22/23 Apple drops 1% to $173.44 after Loop downgrades on guidance risk 05/18/23 OpenAI announces launch of ChatGPT app for iPhone 05/18/23 Apple expands Apple Store online into Vietnam $221.76 / +3.925 (+1.80%)
05/22/23 Wells Fargo Wells Fargo upgrades Norfolk Southern on bottoming intermodal volumes 05/22/23 Wells Fargo Norfolk Southern upgraded to Overweight from Equal Weight at Wells Fargo 05/22/23 Citi Norfolk Southern upgraded to Buy from Neutral at Citi 05/17/23 Evercore ISI Old Dominion upgraded to Outperform at Evercore ISI amid volatility 05/22/23 UBS DraftKings upgraded to Buy from Neutral at UBS 05/15/23 Roth MKM Roth MKM sees winners and losers from internet gaming deals 05/14/23 Citi DraftKings price target raised to $30 from $25 at Citi 05/08/23 Guggenheim DraftKings price target raised to $32 from $27 at Guggenheim 05/22/23 Citi Union Pacific upgraded to Buy from Neutral at Citi 04/21/23 Morgan Stanley Union Pacific price target lowered to $171 from $176 at Morgan Stanley 04/21/23 RBC Capital Union Pacific price target lowered to $184 from $191 at RBC Capital 04/21/23 Stifel Union Pacific price target lowered to $216 from $222 at Stifel 05/22/23 Argus Rocket Companies upgraded to Hold at Argus on narrower 2023 loss 05/22/23 Argus Rocket Companies upgraded to Hold from Sell at Argus 05/08/23 Piper Sandler Rocket Companies price target raised to $8 from $7.50 at Piper Sandler 05/22/23 Truist Truist upgrades Moog to Buy on long-term outlook at investor day next month 05/22/23 Truist Moog upgraded to Buy from Hold at Truist 02/06/23 TD Cowen Moog price target raised to $131 from $122 at Cowen 10/12/22 Truist Moog price target lowered to $75 from $83 at Truist 05/22/23 Loop Capital Loop downgrades Apple on 'material downside risk' to guidance 05/22/23 Loop Capital Apple downgraded to Hold from Buy at Loop Capital 05/15/23 Loop Capital Alphabet downgraded to Hold on AI uncertainties at Loop Capital 05/22/23 Loop Capital Cirrus Logic cut to Hold at Loop Capital on reductions in iPhone work 05/22/23 Loop Capital Cirrus Logic downgraded to Hold from Buy at Loop Capital 05/05/23 Susquehanna Cirrus Logic price target lowered to $95 from $105 at Susquehanna 05/05/23 TD Cowen Cirrus Logic price target lowered to $100 from $110 at TD Cowen 05/22/23 Baird Intercept price target lowered to $18 from $35 at Baird 05/22/23 H.C. Wainwright Intercept downgraded to Sell from Neutral at H.C. Wainwright 05/19/23 Societe Generale Inventiva upgraded to Buy from Sell at Societe Generale 05/17/23 Raymond James Raymond James downgrades Intercept, expects Ocaliva to get CRL in NASH 05/22/23 Deutsche Bank Foot Locker price target lowered to $28 from $42 at Deutsche Bank 05/22/23 Citi Citi opens 'downside catalyst watch' on Nike 05/22/23 Guggenheim Foot Locker price target lowered to $50 from $60 at Guggenheim 05/22/23 Evercore ISI Foot Locker price target lowered to $45 from $60 at Evercore ISI $112.01 / -2.785 (-2.43%)
05/22/23 TD Cowen Foot Locker price target lowered to $26 from $39 at TD Cowen 05/21/23 Williams Trading Nike downgraded to Sell from Hold at Williams Trading 04/19/23 Guggenheim Tapestry named a Best Idea at Guggenheim, replacing Nike 05/22/23 Hovde Group Hovde starts Zions at Outperform, says 'firing on all cylinders' 05/22/23 Hovde Group Zions Bancorp initiated with an Outperform at Hovde Group 05/05/23 JPMorgan Zions Bancorp upgraded to Overweight from Underweight at JPMorgan 05/03/23 Wolfe Research Comerica downgraded to Peer Perform from Outperform at Wolfe Research 05/22/23 Barclays Ormat Technologies initiated with an Equal Weight at Barclays 05/11/23 Roth MKM Ormat Technologies price target lowered to $92 from $93 at Roth MKM 03/01/23 UBS UBS upgrades Ormat to Buy on multiple growth tailwinds 03/01/23 UBS Ormat Technologies upgraded to Buy from Neutral at UBS 05/22/23 Canaccord Dice Therapeutics initiated with Buy, $71 target at Canaccord 05/22/23 Canaccord Dice Therapeutics initiated with a Buy at Canaccord 03/31/23 Needham Dice Therapeutics initiated with a Buy at Needham 03/01/23 TD Cowen Dice Therapeutics initiated with an Outperform at Cowen 05/22/23 CL King CL King starts Conmed with Buy into growth acceleration 05/22/23 CL King Conmed initiated with a Buy at CL King 04/27/23 Stifel Conmed price target raised to $130 from $118 at Stifel 05/22/23 Morgan Stanley BlackLine initiated with an Equal Weight at Morgan Stanley 05/08/23 Truist BlackLine price target lowered to $60 from $65 at Truist 05/08/23 Citi BlackLine upgraded to Neutral from Sell at Citi (Friday) 05/05/23 BMO Capital BlackLine price target lowered to $59 from $71 at BMO Capital 04/19/23 Zions Bancorp reports Q1 EPS $1.33, consensus $1.53 04/19/23 Notable companies reporting after market close 01/23/23 Zions Bancorp reports Q4 EPS $1.84, consensus $1.64 01/23/23 Notable companies reporting after market close 04/20/23 Union Pacific reports Q1 EPS $2.67, consensus $2.59 01/24/23 Union Pacific reports Q4 EPS $2.67, consensus $2.78 01/23/23 Notable companies reporting before tomorrow's open 05/04/23 Rocket Companies sees Q2 adjusted revenue $850M-$1B, consensus $996.1M 05/04/23 Rocket Companies reports Q1 adjusted EPS (6c), consensus (9c) 02/28/23 Rocket Companies sees Q1 adjusted revenue $700M-$850M, consensus $805.81M 05/09/23 Ormat Technologies sees FY23 revenue $823M-$858M, consensus $837.24M 05/09/23 Ormat Technologies reports Q1 adjusted EPS 51c vs 35c last year 02/22/23 Ormat Technologies sees FY23 revenue $823M-$858M, consensus $865.61M 02/22/23 Ormat Technologies reports Q4 adjusted EPS 73c vs 41c last year $221.76 / +3.925 (+1.80%)
04/26/23 Norfolk Southern: Q1 results include $387M charge associated with Eastern Ohio 04/26/23 Norfolk Southern reports Q1 EPS $3.32, consensus $3.12 01/25/23 Norfolk Southern reports Q4 EPS $3.42, consensus $3.44 $112.01 / -2.785 (-2.43%)
03/21/23 Nike sees FY23 revenue up high single digits, gross margins down 250bps 03/21/23 Nike reports Q3 EPS 79c, consensus 55c 03/21/23 Notable companies reporting after market close 12/20/22 Nike sees FY23 revenue growth in mid teens, consensus $49.01B 04/28/23 Moog backs FY23 adjusted EPS view $5.70, consensus $5.71 04/28/23 Moog reports Q2 EPS $1.42, consensus $1.43 02/03/23 Moog backs FY23 adjusted EPS view $5.70, consensus $5.71 02/03/23 Moog reports Q1 adjusted EPS $1.25, consensus $1.28 04/27/23 Intercept reports Q1 EPS (77c), consensus (65c) 03/02/23 Intercept reports Q4 EPS (50c), consensus (16c) 01/11/23 Intercept sees FY22 net sales of $343M, up 10% y/y 05/19/23 Foot Locker cuts FY23 adjusted EPS view to $2.00-$2.25 from $3.35-$3.65 05/19/23 Correction: Foot Locker cuts FY23 adjusted EPS view to $2.00-$2.25 05/19/23 Foot Locker cuts FY23 adjusted EPS view to $3.35-$3.65 from $2.00-$2.25 05/19/23 Foot Locker reports Q1 EPS 70c, consensus 81c 05/04/23 DraftKings raises FY23 revenue view to $3.14B-$3.24B from $2.85B-$3.05B 05/04/23 DraftKings reports Q1 adjusted EPS (51c), consensus (89c) 05/04/23 Notable companies reporting after market close 02/16/23 DraftKings raises FY23 revenue view to $2.85B-$3.05B from $2.8B-$3B 03/15/23 Dice Therapeutics reports Q4 EPS (51c), consensus (49c) 05/04/23 Cirrus Logic sees Q1 revenue $260M-$320M, consensus $326.35M 05/04/23 Cirrus Logic reports Q4 adjusted EPS 92c, consensus 84c 02/02/23 Cirrus Logic sees Q4 revenue $340M-$400M, consensus $372.07M 04/26/23 Conmed raises FY23 EPS view $3.30 to $3.50, from $3.20 to $3.45, consensus $3.32 04/26/23 Conmed reports Q1 EPS 66c, consensus 60c 02/02/23 Conmed sees FY23 adjusted EPS $3.20-$3.45, consensus $3.37 02/02/23 Conmed reports Q4 EPS 86c, consensus 90c 05/04/23 BlackLine sees FY23 EPS $1.23-$1.29, consensus 92c 05/04/23 BlackLine sees Q2 EPS 27c-29c, consensus 19c 05/04/23 BlackLine reports Q1 EPS 34c, consensus 16c 03/06/23 BlackLine reaffirms view FY23 EPS 89c-94c, consensus 92c 05/21/23 Fly Intel: Top five weekend stock stories 05/04/23 Apple sees Q3 revenue growth 'similar' to Q2, consensus $84.71B 05/04/23 Apple sees Q3 revenue 'similar' to Q2, consensus $84.71B 05/04/23 Apple reports Q2 EPS $1.52, consensus $1.43
Initiation
CL King initiated…
CL King initiated coverage of Conmed with a Buy rating and $140 price target. Conmed has the right corporate strategy and management team to accelerate its sales growth and significantly expand margins over the next three years, the analyst tells investors in a research note. The firm believes AirSeal, Buffalo Filter, In2Bones and Biorez are differentiated products that will facilitate the company's growth acceleration and margin expansion story. The stock's valuation "does not fully capture this outlook," contends King.
Show Hide Related Items >> <<
02/02/23 Conmed: Results impacted by implementation of warehouse management system 05/22/23 CL King Conmed initiated with a Buy at CL King 04/27/23 Stifel Conmed price target raised to $130 from $118 at Stifel 04/27/23 Needham Conmed price target raised to $135 from $122 at Needham 04/26/23 Conmed raises FY23 EPS view $3.30 to $3.50, from $3.20 to $3.45, consensus $3.32 04/26/23 Conmed reports Q1 EPS 66c, consensus 60c 02/02/23 Conmed sees FY23 adjusted EPS $3.20-$3.45, consensus $3.37 02/02/23 Conmed reports Q4 EPS 86c, consensus 90c 02/02/23 Fly Intel: After-Hours Movers
Initiation
CL King analyst Kristen…
CL King analyst Kristen Stewart initiated coverage of Avanos with a Buy rating and $31 price target. The firm views the company's transformation process as a catalyst for it to improve its financial profile and for stock price appreciation, and believes Avanos' upcoming investor day should be a positive catalyst, the analyst tells investors in a research note.
Show Hide Related Items >> <<
05/03/23 Avanos falls -16.3% 01/11/23 Avanos announces two executive leadership appointments 05/22/23 CL King Avanos initiated with a Buy at CL King 07/18/22 Stifel Avanos price target lowered to $28 from $37 at Stifel 05/03/23 Avanos backs FY23 adjusted EPS view $1.60-$1.80, consensus $1.70 05/03/23 Avanos reports Q1 adjusted EPS 27c, consensus 27c 02/21/23 Avanos sees FY23 adjusted EPS $1.60-$1.80, consensus $1.68 02/21/23 Avanos reports Q4 adjusted EPS 60c, consensus 49c
Initiation
CL King initiated…
CL King initiated coverage of Conmed with a Buy rating and $140 price target.
Initiation
CL King analyst Kristen…
CL King analyst Kristen Stewart initiated coverage of Avanos with a Buy rating and $31 price target.
Show Hide Related Items >> <<
05/03/23 Avanos falls -16.3% 01/11/23 Avanos announces two executive leadership appointments 07/18/22 Stifel Avanos price target lowered to $28 from $37 at Stifel 05/03/23 Avanos backs FY23 adjusted EPS view $1.60-$1.80, consensus $1.70 05/03/23 Avanos reports Q1 adjusted EPS 27c, consensus 27c 02/21/23 Avanos sees FY23 adjusted EPS $1.60-$1.80, consensus $1.68 02/21/23 Avanos reports Q4 adjusted EPS 60c, consensus 49c
Initiation
CL King initiated…
CL King initiated coverage of Conmed with a Buy rating and $140 price target.
Show Hide Related Items >> <<
02/02/23 Conmed: Results impacted by implementation of warehouse management system 04/27/23 Stifel Conmed price target raised to $130 from $118 at Stifel 04/27/23 Needham Conmed price target raised to $135 from $122 at Needham 04/27/23 Wells Fargo Conmed price target raised to $119 from $96 at Wells Fargo 04/27/23 Piper Sandler Conmed price target raised to $128 from $118 at Piper Sandler 04/26/23 Conmed raises FY23 EPS view $3.30 to $3.50, from $3.20 to $3.45, consensus $3.32 04/26/23 Conmed reports Q1 EPS 66c, consensus 60c 02/02/23 Conmed sees FY23 adjusted EPS $3.20-$3.45, consensus $3.37 02/02/23 Conmed reports Q4 EPS 86c, consensus 90c 02/02/23 Fly Intel: After-Hours Movers
Hot Stocks
Castle Biosciences…
Castle Biosciences announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh. "Castle is proud to be a member of the Pittsburgh community and grow our footprint in this great city," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Our new state-of-the-art laboratory provides us with additional capacity that should allow us to continue to scale our operations in the future. We are excited about the opportunities this new space provides for the growth of our business as well as for our continued impact on patient care." The new 20,000-square-foot facility doubles the size of Castle's previous Pittsburgh laboratory and is located in the city's historic North Side, in the Nova Place complex at 100 S. Commons, Suite 245. Castle expects to have the capacity and ability to process each of its proprietary tests out of the new laboratory. Additionally, Castle is anticipating doubling its workforce in the city, creating approximately 35 new jobs by the end of 2023, including histotechnologist and molecular technologist positions and other jobs in a variety of areas, including laboratory operations, research and development, and information technology. Castle operates clinical laboratories in Pittsburgh and Phoenix. The Company's laboratories are College of American Pathologists CAP accredited and Clinical Laboratory Improvement Amendments CLIA certified, reflecting the Company's commitment to high-quality standards and excellence in patient care. The new laboratory in Pittsburgh brings Castle's total laboratory operations space to more than 52,000 square feet combined.
Show Hide Related Items >> <<
03/19/23 Castle Biosciences announces performance data for DecisionDx-SCC test 01/17/23 Castle up 1.5% after announcing presentation for dermatology conference 01/17/23 Castle to share data on clinical value skin cancer test at Hawaii conference 05/04/23 Baird Castle Biosciences price target lowered to $35 from $38 at Baird 03/01/23 Lake Street Castle Biosciences price target lowered to $41 from $63 at Lake Street 03/01/23 Baird Castle Biosciences price target lowered to $38 from $42 at Baird 01/05/23 Scotiabank Castle Biosciences initiated with an Outperform, $54 target at Scotiabank 05/03/23 Castle Biosciences affirms FY23 revenue view $170M-$180M, consensus $173.4M 05/03/23 Castle Biosciences reports Q1 EPS ($1.10), consensus (89c) 02/28/23 Castle Biosciences sees FY23 revenue of $170M-$180M, consensus $168.3M 02/28/23 Castle Biosciences reports Q4 EPS (78c), consensus (84c)
Hot Stocks
CloudMD Software &…
CloudMD Software & Services and XTM announced a partnership to bring Employee Assistance Program, EAP, and telemedicine to the historically underserved hospitality and service industry. "Inspired workers are a win for employers," said Marilyn Schaffer, CEO, of XTM. "Healthcare creates a lot of noise and distraction for service workers who may have difficulty in accessing a family doctor due to scheduling and the shortage of local professional medical experts. Through our partnership with CloudMD, we dignify the service workforce by offering on-call virtual healthcare as well as short-term mental health support. This service will be offered either through employers or by Members' direct opt-in." The new partnership will allow large chains, individual locations, or individual workers to opt-in at an attractive per-member, per-month cost, enhancing the value of being an XTM member and improving health, wellness, and productivity of participating organizations.
Show Hide Related Items >> <<
04/10/23 CloudMD appoints Dhruv Chandra as CTO 11/16/22 Canaccord CloudMD price target lowered to C$0.25 from C$0.40 at Canaccord 09/15/22 KeyBanc KeyBanc starts CloudMD at Sector Weight, says stock 'underfollowed' 09/15/22 KeyBanc CloudMD initiated with a Sector Weight at KeyBanc 08/24/22 Canaccord CloudMD price target lowered to C$0.40 from C$0.45 at Canaccord
Earnings
Sees FY23 revenue…
Sees FY23 revenue $1.16B-$1.19B, consensus $1.18B
Show Hide Related Items >> <<
01/09/23 Agiliti CEO Tom Leonard to retire, Tom Boehning to succeed 12/19/22 Agiliti to replace LL Flooring in S&P 600 at open on 12/19 12/05/22 Agiliti rises 13.7% 12/05/22 Agiliti rises 11.2% 03/08/23 Citi Agiliti price target lowered to $20 from $21 at Citi 01/06/23 Morgan Stanley Agiliti downgraded to Equal Weight at Morgan Stanley ahead of transition year 01/06/23 Morgan Stanley Agiliti downgraded to Equal Weight from Overweight at Morgan Stanley 12/16/22 BofA Agiliti downgraded to Neutral at BofA on lower visibility 05/09/23 Agiliti reports Q1 adjusted EPS 20c, consensus 16c 03/07/23 Agiliti sees FY23 adjusted EPS 65c-70c, consensus 90c 03/07/23 Agiliti reports Q4 adjusted EPS 18c, consensus 17c 11/10/22 Agiliti sees FY22 EPS 83c-88c, consensus 89c
Earnings
Reports Q1 revenue $300M,…
Reports Q1 revenue $300M, consensus $288.44M. "Our first quarter performance met our expectations with results that reflect the importance of our value proposition," said Tom Boehning, Chief Executive Officer. "Our customers are navigating a broad set of economic challenges, and we are proud to bring solutions that address many of the financial, clinical and operational constraints facing our healthcare system today. This critical work continues to drive the momentum in our business and gives us confidence in our outlook for the year."
Show Hide Related Items >> <<
01/09/23 Agiliti CEO Tom Leonard to retire, Tom Boehning to succeed 12/19/22 Agiliti to replace LL Flooring in S&P 600 at open on 12/19 12/05/22 Agiliti rises 13.7% 12/05/22 Agiliti rises 11.2% 03/08/23 Citi Agiliti price target lowered to $20 from $21 at Citi 01/06/23 Morgan Stanley Agiliti downgraded to Equal Weight at Morgan Stanley ahead of transition year 01/06/23 Morgan Stanley Agiliti downgraded to Equal Weight from Overweight at Morgan Stanley 12/16/22 BofA Agiliti downgraded to Neutral at BofA on lower visibility 03/07/23 Agiliti sees FY23 adjusted EPS 65c-70c, consensus 90c 03/07/23 Agiliti reports Q4 adjusted EPS 18c, consensus 17c 11/10/22 Agiliti sees FY22 EPS 83c-88c, consensus 89c 11/10/22 Agiliti reports Q3 EPS 19c, consensus 16c
